CCK-4
Modify Date: 2024-01-11 11:02:06
CCK-4 structure
|
Common Name | CCK-4 | ||
|---|---|---|---|---|
| CAS Number | 1947-37-1 | Molecular Weight | 596.70 | |
| Density | 1.341g/cm3 | Boiling Point | 1159.2ºC at 760mmHg | |
| Molecular Formula | C29H36N6O6S | Melting Point | N/A | |
| MSDS | USA | Flash Point | 654.8ºC | |
Use of CCK-4Tetragastrin (Cholecystokinin tetrapeptide; CCK-4) is the C-terminal tetrapeptide of gastrin. Tetragastrin can stimulate gastric secretion[1]. Tetragastrin is a Cholecystokinin (CCK-4) receptor agonist[2]. Gastric mucosal protection[3]. |
| Name | tetragastrin |
|---|---|
| Synonym | More Synonyms |
| Description | Tetragastrin (Cholecystokinin tetrapeptide; CCK-4) is the C-terminal tetrapeptide of gastrin. Tetragastrin can stimulate gastric secretion[1]. Tetragastrin is a Cholecystokinin (CCK-4) receptor agonist[2]. Gastric mucosal protection[3]. |
|---|---|
| Related Catalog | |
| In Vitro | The antagonist of histamine H2-receptors, Cimetidine inhibits the stimulatory effect of histamine in vitro and activates Tetragastrin stimulation of the adenylate cyclase activity. Tetragastrin and histamine activate adenylate cyclase of the rat gastric mucosa via different receptors[4]. |
| In Vivo | In inbred Wistar rats treated with N-methyl-N'-nitro-N-nitrosoguanidine, Tetragastrin (s.c.; 1 mg/kg; every other day) treatment significantly reduces the incidence and the number of adenocarcinomas, and has a significantly lower labelling index of the antral mucosa[1]. Tetragastrin has potential for enhancing gastric mucosal protection associated with mucus secretion and/or mucus synthesis on the surface mucosa of rat gastric mucosa. A significant increase in the mucin content was noted in the mucus gel and surface mucosal layer. An increase in mucin in the mucus gel and surface mucosa would thus appear due to the administration of Tetragastrin[3]. Animal Model: Seven-week-old male Wistar rats, each weighing approximately 160 g[3] Dosage: 12, 120, or 400 μg/kg Administration: Administered subcutaneously (s.c.); followed by 50% ethanol-induced gastric injury Result: Caused a significant increase in mucin content in the corpus mucosa and prevented 50% ethanol-induced gastric mucosal damage in a dose-dependent manner. |
| References |
| Density | 1.341g/cm3 |
|---|---|
| Boiling Point | 1159.2ºC at 760mmHg |
| Molecular Formula | C29H36N6O6S |
| Molecular Weight | 596.70 |
| Flash Point | 654.8ºC |
| Exact Mass | 730.27800 |
| PSA | 247.11000 |
| LogP | 4.67950 |
| Vapour Pressure | 0mmHg at 25°C |
| Index of Refraction | 1.643 |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| RIDADR | NONH for all modes of transport |
|
Overexpression of the Promigratory and Prometastatic PTK7 Receptor Is Associated with an Adverse Clinical Outcome in Colorectal Cancer.
PLoS ONE 10 , e0123768, (2015) Biomarkers and novel therapeutic targets are urgently needed in colorectal cancer (CRC). The pseudo tyrosine kinase receptor 7 (PTK7) is involved in planar cell polarity and it is deregulated in vario... |
|
|
CI-988 Inhibits EGFR Transactivation and Proliferation Caused by Addition of CCK/Gastrin to Lung Cancer Cells.
J. Mol. Neurosci. 56 , 663-72, (2015) Cholecystokinin (CCK) receptors are G-protein coupled receptors (GPCR) which are present on lung cancer cells. CCK-8 stimulates the proliferation of lung cancer cells, whereas the CCK2R receptor antag... |
|
|
Synthesis, characterization and in vitro evaluation of new oxorhenium- and oxotechnetium-CCK4 derivatives as molecular imaging agents for CCK2-receptor targeting.
Eur. J. Med. Chem. 45(2) , 423-9, (2010) The goal of this study is to design new (99m)Tc-radiolabelled shortened CCK derivatives that might be suitable for the molecular imaging of cholecystokinin-2 receptors (CCK2-R), these receptors being ... |
| Cholecystokinin Fragment 30-33 Amide |
| cholecystokinin-4 |
| H-Trp-Met-Asp-Phe-NH2 |
| L-Phenylalaninamide,L-tryptophyl-L-methionyl-L-a-aspartyl |
| cholecystokinin tetrapeptide |
| Cholecystokinin fragment 30-33 amide |
| Cholecystokinin C-terminal tetrapeptide |